2856 results about "Thioether" patented technology

A precursor source mixture useful for CVD or ALD of a film comprising: at least one precursor composed of an element selected from the group consisting of Li, Na, K, Rb, Cs, Fr, Be, Mg, Ti, Zr, Hf, Sc, Y, La, V, Nb, Ta, Cr, Mo, W, Mn, Re, Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, B, Al, Ga, In, Tl, Si, Ge, Sn, Pb, As, P, Sb and Bi, to which is bound at least one ligand selected from the group consisting of hydride, alkyl, alkenyl, cycloalkenyl, aryl, alkyne, carbonyl, amido, imido, hydrazido, phosphido, nitrosyl, nitryl, nitrate, nitrile, halide, azide, alkoxy, siloxy, silyl, and halogenated, sulfonated or silyated derivatives thereof, which is dissolved, emulsified or suspended in an inert liquid selected from the group consisting of aliphatic hydrocarbons, aromatic hydrocarbons, alcohols, ethers, aldehydes, ketones, acids, phenols, esters, amines, alkylnitrile, halogenated hydrocarbons, silyated hydrocarbons, thioethers, amines, cyanates, isocyanates, thiocyanates, silicone oils, nitroalkyl, alkylnitrate, and mixtures thereof. The precursor source mixture may be a solution, emulsion or suspension and may consist of a mixture of solid, liquid and gas phases which are distributed throughout the mixture.

The present invention relates to a novel process for the preparation of biologically active antibody dimers in a pharmaceutically acceptable composition. The dimers can be composed of two antibody molecules having the same antigen binding specificity and linked through reducible, disulfide, or a non-reducible thioether, bond (homodimer). Alternatively, the dimers can be composed of two different antibody molecules having binding specificity for two distinct antigens (heterodimer). These dimers are useful for inducing hyper-cross-linking of membrane antigens. The present invention further relates to the use of biologically active antibody dimers for the preferential killing or inhibition of selected cell populations in the treatment of diseases such as cancer and autoimmune disorders.

Disclosed are polythioethers that are the reaction product of reactants that include: a) an isocyanurate-containing trithiol; b) a polythiol different from (a); and c) a diene. Also disclosed are compositions, such as sealant compositions, that include such polythioethers.

The light emitting device of the present invention relates to a light emitting device which is characterized in that it is a device with an emissive substance present between an anode and cathode, and which emits light by means of electrical energy, and said device has a least one type of compound denoted by (a) to (d) below. (a) A compound having a plurality of 1,7-phenanthroline skeletal structures (b) A benzoquinoline derivative (c) A spiro compound represented by general formula (1) A1 and A2 are each selected from single bonds, substituted or unsubstituted alkyl chains, ether chains, thioether chains, ketone chains and substituted or unsubstituted amino chains. However, A1<> A2. Z represents carbon or silicon. R1 to R16 are each selected from hydrogen, alkyl group, cycloalkyl group, aralkyl group, alkenyl group, cycloalkenyl group, alkynyl group, hydroxyl group, mercapto group, alkoxy group, alkylthio group, aryl ether group, aryl thioether group, aryl group, heterocyclic group, halogen, haloalkane, haloalkene, haloalkyne, cyano group, aldehyde group, carbonyl group, carboxyl group, ester group, carbamoyl group, amino group, nitro group, silyl group, siloxanyl group and a cyclic structure formed with an adjacent substituent. (d) A tetraphenylmethane derivative represented by general formula (2) R17 to R36 are each selected from hydrogen, alkyl group, cycloalkyl group, aralkyl group, alkenyl group, cycloalkenyl group, alkynyl group, hydroxyl group, mercapto group, alkoxy group, alkylthio group, aryl ether group, aryl thioether group, aryl group, heterocyclic group, halogen, haloalkane, haloalkene, haloalkyne, cyano group, aldehyde group, carbonyl group, carboxyl group, ester group, carbamoyl group, amino group, nitro group, silyl group, siloxanyl group and a cyclic structure formed with an adjacent substituent. However, at least one of R17 to R36 is selected from substituents represented by general formula (3). -X-Ar (3) X is a single bond or is selected from the following, and Ar denotes a condensed aromatic ring or heteroaromatic ring. In the case where X is phosphorus oxide, then Ar represents an aromatic hydrocarbon or heteroaromatic ring. n is an natural number.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

The invention provide a class of chain-extended polysiloxane crosslinkers which comprises (1) at least two polysiloxane segments, wherein each pair of adjacent polysiloxane segments is linked by one divalent organic radical which includes at least one pendant hydrophilic group (hydroxyl and/or carboxyl groups) or at least one dangling hydrophilic polymer chain and a di-thioether linkage —S-DR—S— in which DR is a divalent organic radical; and (2) two terminal ethylenically unsaturated groups. The present invention is also related to a polymer comprising crosslinking units derived from chain-extended polysiloxane crosslinker of the invention and to ophthalmic lenses comprising such a polymer.

A composition comprising a polymer comprising a repeat unit of Formula I.: wherein R<1 >is independently in each occurrence H, C1-40 hydrocarbyl or C3-40 hydrocarbyl containing one or more S, N, O, P or Si atoms, or both of R<1 >together with the 9-carbon on the fluorene, may form a C5-20 ring structure which may contain one or more S, N, or O atoms; R2 is independently in each occurrence C1-20 hydrocarbyl, C1-20 hydrocarbyloxy, C1-20 thioether, C1-20 hydrocarbyloxycarbonyl, C1-20 hydrocarbylcarbonyloxy, or cyano; a is independently in each occurrence, 0 or 1; X is O, S, SO2, C(R<3>)2 or N-R<3 >wherein R<3 >is aryl or substituted aryl of C6 to C40, aralkyl of C6 to C24, or alkyl of C1 to C24. Preferably R<3 >is aryl of C6 to C24 and more preferably R<3 >is an alkylated aryl group of C6 to C24; Ar is an aryl or heteroaryl group of C6 to C40 or substituted aryl or heteroaryl group of C6 to C40, preferably C6-C24, and most preferably C6-C14. Y is a conjugated moiety that can vary in each occurrence of the repeat unit.

A hydrosilylation catalyst is provided wherein a platinum catalyst is enclosed in a heat-fusible compound having a melting point of 40-200 DEG C. and containing an aliphatic unsaturated bond, carbonyl, carboxyl or thioether radical in a molecule. The catalyst is blended in organo-polysiloxane to form a silicone composition having both shelf stability and fast-curing capability.

The inventions disclosed herein relate to genuses of non-naturally occurring small molecule compounds which comprise two or optionally three organic moieties of limited size “linked” by certain structurally related “linker” functional groups. Suitable linker groups include ester, amine, ether, keto, imino, thioamide, thioether, sulfonamide, sulfonate ester, sulfone, guanidine, and thiourea groups. The compounds are capable, when contacted with comestible food or drinks or pharmaceutical compositions, at concentrations preferably on the order of about 100 ppm or lower, of serving as savory (“umami”) or sweet taste modifiers, savory or sweet flavoring agents and savory or sweet flavor enhancers, for use in foods, beverages, and other comestible or orally administered medicinal products or compositions, optionally in the presence of or in mixtures with conventional flavoring agents such as monosodium glutamate or known natural or artificial sweeteners.

The present invention belongs to gas producing technology. The absorbing liquid for eliminating sulfide from gas mixture includes main absorbent comprising steric hindrance amine and N-methyl diethanolamine; cosolvent of one or several of sulfolane, N-methyl pyrrolidine, polyglycol dialkyl ether, morpholine and its derivative; catalyst of one or several of C2-C12 alkanolamine, piperazine and its derivative, quinoline, urea and metal phthalocyanine complex. Using the absorbing liquid can eliminate H2S, COS, mercaptan, thioether and other sulfide in less steps.

A method of preparing an antioxidant polymer includes forming or obtaining a first polymer having reactive pendant groups, where the first polymer does not include cyclic anhydride repeat units, and derivatizing the first polymer with an antioxidant. Another method of preparing an antioxidant polymer includes forming or obtaining a first polymer having reactive pendant groups and derivatizing the first polymer with an antioxidant, where the antioxidant is attached to the first polymer by an acetal, amide, amine, carbamate, carbonate, ester, ether or thioether linkage or by a carbon-carbon bond. The invention is also directed to polymers that are generally prepared by these methods, compositions that include such polymers and methods of using such polymers.

The invention relates to a production method for ultra-low sulfur and high-octane number gasoline. The method comprises the following steps of: filling a poor-quality full range gasoline raw material in a reaction distillation column to contact the material with a sulfoether catalyst to perform a sulfur ether reaction and fraction cutting so that low-boiling point sulfides, such as thiol and thiophene, are converted into high-boiling point sulfoether which is then transferred into heavy fraction gasoline, wherein the cutting fractionation temperature of light fraction gasoline and the heavy fraction gasoline is 50 to 90 DEG C; contacting the light fraction gasoline with a hydrocarbon highly branched isomerization catalyst; contacting the heavy fraction gasoline with a selective hydrodesulfurization catalyst and a desulfurization-hydrocarbon isomerization/aromatization catalyst; and mixing the treated light fraction gasoline and the heavy fraction gasoline to obtain the ultra-low sulfur and high-octane number gasoline. The method is suitable for modifying poor-quality gasoline, can reach better desulfurization and olefin reduction effects on ultra-high sulfur and high-olefin poor-quality catalytic gasoline, and can maintain or increase the octane number of the product and keep a higher product yield after reaction.

The present invention provides a thioether bond structure-containing hindered phenol antioxidant and a preparation method thereof, wherein screen phenol, thiol ester and formaldehyde in a reaction medium are subjected to a reaction under a certain condition in the presence of a catalyst to obtain a thioether bond-containing hindered phenol antioxidant compound, wherein the compound has an excellent antioxidation performance in hydrogenation base oil, and can be adopted as a lubricating agent antioxidant to be separately used or is compounded with other additives to be used, and the antioxidant is applicable for internal combustion engine oils and industrial lubricating oils.

An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

The invention relates to a lubricant composition for a gasoline engine. The lubricant composition contains: by mass, less than or equal to 0.08% of phosphorus and less than or equal to 0.9% of sulfate ash. The lubricant composition comprises A) a composite antioxidant comprising at least ingredients of 1, an alkylated diphenylamine antioxidant, 2, a thiophenolic ester antioxidant and 3, an unessential phenolic thioether antioxidant, B) a polyisobutylene succinimide ashless dispersant and/or a boronized polyisobutylene succinimide dispersant, C) one or more alkaline earth metal salicylate cleaning agents, D) at least one zinc dialkyl dithiophosphate, E) one or more oil-soluble organic molybdenum friction modifiers, F) one or more ashless friction modifiers, and G) a main amount of lubricating base oil. The lubricant composition for a gasoline engine has synergistic effect of the additives, can satisfy antioxidation requirements of a high-grade gasoline engine lubricant, and has excellent piston cleanliness, wear resistance and a viscosity increasing control capacity.

A high-toughness filler reinforced polyphenylthioether material with flame-retarding, thermal stable and mechanical performance is proportionally prepared from polyphenylthioether, glass fibres, inorganic mineral filler, impact modifier, coupling agent, antioxidizing agent and assistant.

The present invention is directed to acrylated urethanes including the reaction product of: (1)(a) at least one urethane having at least two isocyanate groups and at least one acrylate group; and (b) at least one alcohol compound having at least two hydroxyl groups; or (2) (a) at least one isocyanate functional urethane which is the reaction product of at least one alcohol compound selected from the group consisting of amino alcohols, thioether alcohols, phosphino alcohols and mixtures thereof and at least one polyisocyanate; and (b) at least one hydroxy-functional material having at least one acrylate group; curable compositions including the same and processes for making the same.

The invention discloses a cyclopropylfluoroquinolone C-3 s-triazole thioether ketone thiosemicarbazone compound and a preparation method and application thereof. The chemical general structure of the compound is shown in formula I, in which R is at least one of H, ether group, hydroxyl, methyl, halogeno-group and nitro. According to the cyclopropylfluoroquinolone C-3 s-triazole thioether ketone thiosemicarbazone compound disclosed by the invention, a fluoroquinolone framework is actively overlaid or structurally complemented with three different pharmacophores such as a s-triazole heterocyclic ring, thiosemicarbazone and the like, so that the anti-tumor activity of the novel compound is increased, the toxic and side effects of normal cells are reduced, and the compound can serve as an anti-tumor activity matter to develop an anti-tumor drug of a novel structure.